#None #Toronto #AAV Gene Therapy #Xtalks #titer assays

Overview of AAV Gene Therapy and Titer Assays

Adeno-associated virus (AAV) gene therapy has been making significant strides in recent years due to its potential to treat a variety of genetic disorders. However, one of the primary hurdles in the development of AAV therapies is ensuring reliable capsid titer measurement, a critical analytical requirement. The upcoming webinar hosted by Xtalks will delve into how regulatory-ready titer assays can mitigate risks associated with Good Manufacturing Practices (GMP) in this field.

Importance of Capsid Titer Measurement

In AAV gene therapy development, accurately measuring the capsid titer is essential. This quantification helps determine the efficacy of the viral vector, influencing both process decisions and quality assessments of the final product. As the market evolves, so too does the need for robust methodologies that comply with regulatory frameworks, particularly in the GMP environment.

Challenges in GMP and Titer Assays

Transitioning titer assays from a development phase to a GMP-regulated quality control setting poses distinct challenges. This webinar aims to address these issues by examining a validated analytical method for quantifying AAV9 capsid titer using a commercially available titer kit. The speakers will focus on the validation requirements stipulated under ICH Q2 and Q14 guidelines, including parameters such as specificity, precision, accuracy, and system suitability.

What to Expect in the Webinar

Attendees can expect a thorough exploration of an automated immunoassay tailored for GMP application. The automation of the process not only enhances efficiency but also significantly minimizes sample consumption, which is especially vital when dealing with limited or complex gene therapy materials. Participants will gain insights into the practical implementation of these assays and how they support regulatory compliance.

The session will also discuss specific performance characteristics and share validation results that bolster the robustness of the assay. This information will be invaluable for those striving for improved QA/QC workflows in AAV programs.

The Bigger Picture: CDMO Approach

In addition to the technical aspects, the webinar will frame this discussion within the broader context of Contract Development and Manufacturing Organizations (CDMO). AAV-based gene therapies often require a harmonious blend of scalable technologies, comprehensive QC methods, and GMP manufacturing capabilities throughout various stages of product development.

Practical Insights from Industry Experts

Joining the webinar are Linda Klauss, Senior Field Application Scientist at Gyros Protein Technologies, and Matthias Gora, Senior Technician at Ascend Advanced Therapies GmbH. Their combined experience will provide attendees with practical insights into achieving consistent and reproducible capsid titer analysis across the development lifecycle.

Registration and Details

The live webinar is scheduled for Tuesday, November 24, 2026, at 9:30 AM EST (3:30 PM CET). Participants interested in understanding AAV gene therapy titer assay validation processes are encouraged to register early to secure their place. This session promises to empower professionals in the biotech sector with knowledge critical to advancing AAV therapeutic development.

For more information or to register, visit the official Xtalks website. Don't miss this opportunity to enhance your understanding of titer assays in the context of GMP readiness!

Conclusion

As the field of gene therapy continues to progress, having reliable analytical methods in place is crucial. The upcoming Xtalks webinar will provide the necessary tools and insights for professionals navigating the complexities of AAV therapy development and GMP compliance. Join the conversation and stay ahead in this innovative and rapidly evolving industry.